Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2019

Open Access 01-01-2019 | Original Paper

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy

Authors: Markus Kieler, Matthias Unseld, Johann Wojta, Alexandra Kaider, Daniela Bianconi, Svitlana Demyanets, Gerald W. Prager

Published in: Medical Oncology | Issue 1/2019

Login to get access

Abstract

Interleukin-33 (IL-33) and its “decoy” receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2 plasma levels were assessed in 20 patients with advanced PDAC before start of systemic chemotherapy and were analyzed in relation to clinical outcome. Kaplan Meier and multivariable Cox proportional hazards model analysis revealed a significant association between sST2 plasma levels and survival (HR 2.10, 95% CI 1.33–3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy.
Literature
1.
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913–21.CrossRef
2.
Zheng L, Xue J, Jaffee EM, et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144:1230–40.CrossRef
3.
Liew FY, Girard J, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676–89.CrossRef
4.
Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31:2080–9.CrossRef
5.
Stojkovic S, Kaun C, Heinz M, et al. Interleukin-33 induces urokinase in human endothelial cells–possible impact on angiogenesis. J Thromb Haemost. 2014;12:948–57.CrossRef
6.
Montanari E, Stojkovic S, Kaun C, et al. Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells. Thromb Haemost. 2016;116:317–27.CrossRef
7.
Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.CrossRef
8.
Nishida A, Andoh A, Imaeda H, et al. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut. 2010;59:531–41.CrossRef
9.
Masamune A, Watanabe T, Kikuta K, et al. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2010;299:821–32.CrossRef
10.
Mohammed A, Janakiram NB, Madka V, et al. Lack of chemopreventive effects of P2 × 7R inhibitors against pancreatic cancer. Oncotarget. 2017;8:97822–34.PubMedPubMedCentral
11.
Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and Interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS ONE. 2014;9:e95055.CrossRef
12.
Demyanets S, Tentzeris I, Jarai R, et al. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine. 2014;67:65–70.CrossRef
13.
Krychtiuk KA, Stojkovic S, Lenz M, et al. Predictive value of low interleukin-33 in critically ill patients. Cytokine. 2018;103:109–13.CrossRef
14.
Stojkovic S, Kaider A, Koller L, et al. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2. J Cell Mol Med. 2018;22:2422–9.CrossRef
15.
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.CrossRef
16.
Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57:114–9.CrossRef
17.
Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231:180–9.CrossRef
18.
Liu X, Zhu L, Lu X, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014;453:486–92.CrossRef
19.
Cui G, Qi H, Gundersen MD, et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother. 2015;64:181–90.CrossRef
20.
Kim JY, Lim S-C, Kim G, et al. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene. 2015;34:4928–38.CrossRef
21.
Yu XX, Hu Z, Shen X, et al. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci. 2015;60:1265–72.CrossRef
22.
Tong X, Barbour M, Hou K, et al. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol. 2016;10:113–25.CrossRef
23.
Akimoto M, Hayashi J-I, Nakae S, et al. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016;7:e2057.CrossRef
24.
Wang Z, Xu L, Chang Y, et al. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. Tumor Biol. 2016;37:11127–34.CrossRef
25.
Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012;60:514–21.CrossRef
26.
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.CrossRef
27.
Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537–47.CrossRef
28.
Tassi E, Gavazzi F, Albarello L, et al. Carcinoembryonic antigen-specific but not antiviral CD4 + T cell immunity is impaired in pancreatic carcinoma patients. J Immunol. 2008;181:6595–603.CrossRef
29.
De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469–78.CrossRef
30.
Kim MS, Kim E, Heo JS, et al. Circulating IL-33 level is associated with the progression of lung cancer. Lung Cancer. 2015;90:346–51.CrossRef
31.
Yang ZP, Ling DY, Xie YH, et al. The association of serum IL-33 and sST2 with breast cancer. Dis Markers. 2015;2015:516895.PubMedPubMedCentral
32.
Bergis D, Kassis V, Radeke HH. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomarkers. 2016;16:117–25.CrossRef
33.
Sun P, Ben Q, Tu S, et al. Serum Interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011;56:3596–601.CrossRef
34.
Lu D, Zhou X, Yao L, et al. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014;14:198.CrossRef
35.
Zeng X, Zhang Z, Gao Q-Q, et al. Clinical significance of serum interleukin-31 and interleukin-33 levels in patients of endometrial cancer: a case control study. Dis Markers. 2016;2016:1–7.CrossRef
36.
Zhang P, Liu X-K, Chu Z, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res. 2012;40:1654–61.CrossRef
37.
Hu L-A, Fu Y, Zhang D-N, et al. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:2563–6.CrossRef
38.
Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 2013;6:311–8.CrossRef
39.
Ketelaar ME, Nawijn MC, Shaw DE, et al. The challenge of measuring IL-33 in serum using commercial ELISA: lessons from asthma. Clin Exp Allergy. 2016;46:884–7.CrossRef
40.
Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–7.CrossRef
41.
Theocharis AD, Tsara ME, Papageorgacopoulou N, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta. 2000;1502:201–6.CrossRef
42.
Kadaba R, Birke H, Wang J, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013;230:107–17.CrossRef
43.
Gao X, Wang X, Yang Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8 + T and NK cells. J Immunol. 2015;194:438–45.CrossRef
44.
Akimoto M, Maruyama R, Takamaru H, et al. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Commun. 2016;7:13589.CrossRef
45.
Saranchova I, Han J, Huang H, et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33. Sci Rep. 2016;6:30555.CrossRef
46.
Brunner SM, Rubner C, Kesselring R, et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology. 2015;61:1957–67.CrossRef
47.
Fang Y, Zhao L, Xiao H, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol. 2017;34:1–9.CrossRef
48.
Serrels B, McGivern N, Canel M, et al. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Sci Signal. 2017;10:eaan8355.CrossRef
Metadata
Title
Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
Authors
Markus Kieler
Matthias Unseld
Johann Wojta
Alexandra Kaider
Daniela Bianconi
Svitlana Demyanets
Gerald W. Prager
Publication date
01-01-2019
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1223-3

Other articles of this Issue 1/2019

Medical Oncology 1/2019 Go to the issue

Short Communication

Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia

Original Paper

The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma

Original Paper

Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma

Original Paper

The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target

Short Communication

Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer

Original Paper

Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits